

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) An antibody comprising two heavy chain variable regions and two light chain variable regions, wherein the antibody is a single chain polypeptide having a binding activity against human leukocyte antigen (HLA).
2. (Original) The antibody of claim 1, wherein the two heavy chain variable regions and two light chain variable regions are arranged in the order of heavy chain variable region, light chain variable region, heavy chain variable region, and light chain variable region, starting from the N terminus of the single chain polypeptide.
3. (Currently Amended) The antibody of claim 1 ~~[[or 2]]~~, wherein the two heavy chain variable regions and two light chain variable regions are linked by a linker.
4. (Original) The antibody of claim 3, wherein the linker comprises 15 amino acids.
5. (Currently Amended) The antibody of claim 1 ~~any one of claims 1 to 4~~, wherein HLA is HLA class I.
6. (Original) The antibody of claim 5, wherein HLA class I is HLA-A.
7. (Currently Amended) The antibody of claim 1 ~~any one of claims 1 to 6~~, wherein the antibody is sc(Fv)₂.

8. (Original) An sc(Fv)2 comprising heavy chain variable regions that comprise CDR1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOs: 3, 4, and 5.

9. (Original) An sc(Fv)2 comprising light chain variable regions that comprise CDR 1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOs: 6, 7, and 8.

10. (Original) An sc(Fv)2 comprising heavy chain variable regions that comprise CDR1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOs: 3, 4, and 5, and light chain variable regions that comprise CDR 1, 2, and 3 consisting of the amino acid sequences of SEQ ID NOs: 6, 7, and 8.

11. (Original) An sc(Fv)2 comprising heavy chain variable regions that comprise the amino acid sequence of SEQ ID NO: 10.

12. (Original) An sc(Fv)2 comprising light chain variable regions that comprise the amino acid sequence of SEQ ID NO: 12.

13. (Original) An sc(Fv)2 comprising heavy chain variable regions that comprise the amino acid sequence of SEQ ID NO: 10, and light chain variable regions that comprise the amino acid sequence of SEQ ID NO: 12.

14. (Original) An sc(Fv)2 comprising the amino acid sequence of SEQ ID NO: 14.

15. (Original) An sc(Fv)2 comprising the amino acid sequence of SEQ ID NO: 2.

16. (Original) An sc(Fv)2 comprising an amino acid sequence with one or more amino acid substitutions, deletions, additions, and/or insertions in the amino acid sequence of any one

of claims 8 to 15, wherein the sc(Fv)₂ also has an activity equivalent to that of the antibody of any one of claims 8 to 15.

17. (Currently Amended) A polynucleotide encoding the antibody of claim 1 ~~any one of claims 1 to 16~~.

18. (Currently Amended) A polynucleotide that hybridizes with the polynucleotide of claim 17 under stringent conditions, and encodes an antibody having ~~an activity equivalent to the antibody of any one of claims 1 to 16~~ a binding activity against human leukocyte antigen (HLA).

19. (Currently Amended) A vector comprising the polynucleotide of claim 17 ~~[[or 18]]~~.

20. (Currently Amended) A host cell carrying the polynucleotide of claim 17 ~~or 18, or the vector of claim 19~~.

21. (Currently Amended) A method for producing the antibody of claim 1 ~~any one of claims 1 to 16~~, wherein the method comprises the steps of:

- (a) preparing an HLA-recognizing antibody;
- (b) producing a polynucleotide encoding the antibody of claim 1 ~~any one of claims 1 to 16~~ based on the sequence of the antibody prepared in (a);
- (c) constructing a vector comprising the polynucleotide of (b);
- (d) introducing the vector of (c) into host cells; and
- (e) culturing the host cells of (d).

22. (Currently Amended) A cell death-inducing agent comprising the antibody of claim 1 ~~any one of claims 1 to 16~~ as an active ingredient.

23. (Original) The cell death-inducing agent of claim 22, wherein the agent has cell death inducing activity against B cells or T cells.

24. (Original) The cell death-inducing agent of claim 23, wherein the B cells or T cells are activated B cells or activated T cells.

25. (Currently Amended) A cell growth inhibitory agent comprising the antibody of claim 1 ~~any one of claims 1 to 16~~ as an active ingredient.

26. (Currently Amended) An antitumor agent comprising the antibody of claim 1 ~~any one of claims 1 to 16~~ as an active ingredient.

27. (Original) The antitumor agent of claim 26, wherein the tumor is a blood tumor.

28. (Currently Amended) A therapeutic agent for autoimmune diseases, wherein the agent comprises the antibody of claim 1 ~~any one of claims 1 to 16~~ as an active ingredient.